NASDAQ:AVTE Aerovate Therapeutics (AVTE) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free AVTE Stock Alerts $29.57 +1.07 (+3.75%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$27.10▼$29.9950-Day Range$17.68▼$29.5752-Week Range$9.41▼$29.99Volume216,915 shsAverage Volume119,992 shsMarket Capitalization$823.91 millionP/E RatioN/ADividend YieldN/APrice Target$49.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Aerovate Therapeutics alerts: Email Address Aerovate Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside66.8% Upside$49.33 Price TargetShort InterestHealthy5.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 26 Articles This WeekInsider TradingSelling Shares$1.01 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.71) to ($2.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.88 out of 5 starsMedical Sector658th out of 938 stocksPharmaceutical Preparations Industry310th out of 438 stocks 3.3 Analyst's Opinion Consensus RatingAerovate Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $49.33, Aerovate Therapeutics has a forecasted upside of 66.8% from its current price of $29.57.Amount of Analyst CoverageAerovate Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.30% of the float of Aerovate Therapeutics has been sold short.Short Interest Ratio / Days to CoverAerovate Therapeutics has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Aerovate Therapeutics has recently decreased by 10.52%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAerovate Therapeutics does not currently pay a dividend.Dividend GrowthAerovate Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVTE. Previous Next 2.9 News and Social Media Coverage News SentimentAerovate Therapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Aerovate Therapeutics this week, compared to 1 article on an average week.Search Interest6 people have searched for AVTE on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Aerovate Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aerovate Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,010,853.00 in company stock.Percentage Held by Insiders19.30% of the stock of Aerovate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aerovate Therapeutics are expected to decrease in the coming year, from ($2.71) to ($2.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aerovate Therapeutics is -10.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aerovate Therapeutics is -10.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAerovate Therapeutics has a P/B Ratio of 5.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Aerovate Therapeutics Stock (NASDAQ:AVTE)Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Read More AVTE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVTE Stock News HeadlinesMarch 28, 2024 | insidertrades.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells 3,432 SharesMarch 21, 2024 | insidertrades.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells $138,224.00 in StockMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 16, 2024 | insidertrades.comGeorge A. Eldridge Sells 2,016 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) StockMarch 12, 2024 | insidertrades.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider George A. Eldridge Sells 3,433 SharesMarch 29, 2024 | americanbankingnews.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Benjamin T. Dake Sells 3,432 SharesMarch 27, 2024 | globenewswire.comAerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International ConferenceMarch 27, 2024 | finance.yahoo.comAerovate Therapeutics Inc (AVTE) Reports Increased R&D Expenses and Net Loss in 2023March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 27, 2024 | americanbankingnews.comAerovate Therapeutics (NASDAQ:AVTE) Reaches New 52-Week High at $28.39March 26, 2024 | finanznachrichten.deAerovate Therapeutics, Inc.: Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business HighlightsMarch 26, 2024 | americanbankingnews.comAerovate Therapeutics (NASDAQ:AVTE) Now Covered by Jefferies Financial GroupMarch 26, 2024 | markets.businessinsider.comAerovate Therapeutics: A Strong Buy Ahead of Key Clinical Data ReleaseMarch 25, 2024 | benzinga.comRecap: Aerovate Therapeutics Q4 EarningsMarch 25, 2024 | investorplace.comAVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q4 2023March 25, 2024 | markets.businessinsider.comAerovate Therapeutics Announces Full-Year 2023 Financial Results and Business HighlightsMarch 25, 2024 | globenewswire.comAerovate Therapeutics Announces Full-Year 2023 Financial Results and Business HighlightsMarch 24, 2024 | morningstar.comAerovate Therapeutics Inc AVTEMarch 21, 2024 | finance.yahoo.comInsider Sell: Aerovate Therapeutics Inc's (AVTE) Chief Technical Officer Marinus Verwijs Sells ...March 21, 2024 | finance.yahoo.comChief Medical Officer Hunter Gillies Sells 7,000 Shares of Aerovate Therapeutics Inc (AVTE)March 19, 2024 | americanbankingnews.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Sees Significant Decrease in Short InterestMarch 6, 2024 | globenewswire.comAerovate Therapeutics Board of Directors Appoints Habib Dable as Board ChairFebruary 26, 2024 | benzinga.comAerovate Therapeutics Stock (NASDAQ:AVTE) Dividends: History, Yield and DatesJanuary 7, 2024 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Aerovate Therapeutics (AVTE)December 29, 2023 | finance.yahoo.comCompanies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In GrowthDecember 16, 2023 | finance.yahoo.comInsider Sell Alert: Chief Medical Officer Hunter Gillies Sells 12,000 Shares of Aerovate ...November 28, 2023 | markets.businessinsider.comBuy Rating Affirmed: Aerovate Therapeutics’ AV-101 Shows Strong Potential Amid Successful IMPAHCT Trial ProgressionSee More Headlines Receive AVTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2021Today3/29/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AVTE CUSIPN/A CIK1798749 Webaerovatetx.com Phone617-443-2400FaxN/AEmployees43Year FoundedN/APrice Target and Rating Average Stock Price Target$49.33 High Stock Price Target$65.00 Low Stock Price Target$35.00 Potential Upside/Downside+66.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-61.62% Return on Assets-55.08% Debt Debt-to-Equity RatioN/A Current Ratio7.04 Quick Ratio9.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.19 per share Price / Book5.70Miscellaneous Outstanding Shares27,860,000Free Float22,329,000Market Cap$823.82 million OptionableNot Optionable Beta1.18 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Timothy P. Noyes M.B.A. (Age 62)CEO & Director Comp: $703.8kMr. George A. Eldridge (Age 61)CFO & Treasurer Comp: $533.89kDr. Marinus Verwijs Ph.D. (Age 48)Chief Technical Officer Comp: $439.88kDr. Benjamin T. Dake Ph.D. (Age 48)Founder, President, COO & Secretary Comp: $435.5kDr. Ralph W. Niven M.B.A. (Age 64)M.R, Ph.D., Pharm.S, Chief Scientific Officer Comp: $372.33kMr. Hunter Gillies M.D. (Age 58)Chief Medical Officer Comp: $512.74kMr. Timothy J. Pigot (Age 53)Chief Commercial Officer Ms. Donna DeaHead of Regulatory AffairsMs. Susan FischerSenior Vice President of Development OperationsMr. Stephen K. YuSenior Vice President of QualityMore ExecutivesKey CompetitorsAurinia PharmaceuticalsNASDAQ:AUPHApplied TherapeuticsNASDAQ:APLTOPKO HealthNASDAQ:OPKLongboard PharmaceuticalsNASDAQ:LBPHEnliven TherapeuticsNASDAQ:ELVNView All CompetitorsInsiders & InstitutionsBenjamin T DakeSold 11,068 sharesTotal: $309,571.96 ($27.97/share)Benjamin T DakeSold 3,432 sharesTotal: $96,130.32 ($28.01/share)Marinus VerwijsSold 5,300 sharesTotal: $138,224.00 ($26.08/share)George A EldridgeSold 2,016 sharesTotal: $50,440.32 ($25.02/share)Vanguard Group Inc.Bought 27,729 shares on 3/11/2024Ownership: 2.265%View All Insider TransactionsView All Institutional Transactions AVTE Stock Analysis - Frequently Asked Questions Should I buy or sell Aerovate Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerovate Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AVTE shares. View AVTE analyst ratings or view top-rated stocks. What is Aerovate Therapeutics' stock price target for 2024? 3 Wall Street research analysts have issued 1-year price objectives for Aerovate Therapeutics' shares. Their AVTE share price targets range from $35.00 to $65.00. On average, they anticipate the company's stock price to reach $49.33 in the next year. This suggests a possible upside of 66.8% from the stock's current price. View analysts price targets for AVTE or view top-rated stocks among Wall Street analysts. How have AVTE shares performed in 2024? Aerovate Therapeutics' stock was trading at $22.63 on January 1st, 2024. Since then, AVTE shares have increased by 30.7% and is now trading at $29.57. View the best growth stocks for 2024 here. Are investors shorting Aerovate Therapeutics? Aerovate Therapeutics saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 903,700 shares, a drop of 10.5% from the February 29th total of 1,010,000 shares. Based on an average trading volume of 102,500 shares, the days-to-cover ratio is currently 8.8 days. Currently, 5.3% of the company's stock are sold short. View Aerovate Therapeutics' Short Interest. When is Aerovate Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our AVTE earnings forecast. How were Aerovate Therapeutics' earnings last quarter? Aerovate Therapeutics, Inc. (NASDAQ:AVTE) posted its earnings results on Sunday, November, 14th. The company reported ($0.26) EPS for the quarter, meeting the consensus estimate of ($0.26). When did Aerovate Therapeutics IPO? Aerovate Therapeutics (AVTE) raised $100 million in an IPO on Wednesday, June 30th 2021. The company issued 7,150,000 shares at a price of $13.00-$15.00 per share. Who are Aerovate Therapeutics' major shareholders? Aerovate Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Great Point Partners LLC (3.75%), Vanguard Group Inc. (2.27%), Vanguard Group Inc. (2.27%), Point72 Asset Management L.P. (1.60%), Octagon Capital Advisors LP (1.46%) and Vestal Point Capital LP (1.45%). Insiders that own company stock include Benjamin T Dake, Cormorant Asset Management, Lp, George A Eldridge, Hunter Gillies, Marinus Verwijs, Ralph Niven and Timothy P Noyes. View institutional ownership trends. How do I buy shares of Aerovate Therapeutics? Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVTE) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & CompanyMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.